Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - IND
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS Further Development Plans – U.S. FDA Pre-IND Response Timing Confirmed; European Patent Allowance 9/16/2014 3:02:34 PM
Sangamo BioSciences, Inc. (SGMO) Announces Target Date For First IND For Sangamo's In Vivo ZFN Genome-Editing Platform For Monogenic Diseases 9/10/2014 8:04:39 AM
Molecular Templates Inc. Templates Announces FDA Approval Of Investigational New Drug Application For CD20 Internalizing Immunotoxin MT-3724 9/8/2014 10:49:56 AM
Cellectar Biosciences  (NVLT) Announces Acceptance Of Investigational New Drug Application To Evaluate I-131-CLR1404 In Clinical Trials In Relapsed Or Refractory Multiple Myeloma 9/4/2014 8:59:37 AM
Glenmark Pharmaceuticals Enters Oncology With The Discovery And Initiation Of IND Enabling Studies Of An Innovative Bispecific Antibody 8/20/2014 7:38:17 AM
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces FDA Acceptance Of IND To Commence Clinical Trial Of VC-01™ Candidate Cell Replacement Therapy For Type 1 Diabetes 8/19/2014 7:53:57 AM
FDA Grants Orphan Drug Designation For Oncosynergy's Investigational Monoclonal Antibody OS2966 In The Treatment Of Glioblastoma 8/12/2014 8:29:22 AM
Cellectar Biosciences  (NVLT) Files Investigational New Drug Application To Evaluate I-131-CLR1404 In Clinical Trials In Relapsed Or Refractory Multiple Myeloma 8/11/2014 7:38:21 AM
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014 7:24:07 AM
IntelliCell BioSciences (SVFC) Files Pre-IND With FDA For Osteoarthritis Lead By Dr. James Andrews 8/4/2014 11:29:04 AM
Fate Therapeutics (FATE) Announces FDA Clearance Of IND For Clinical Development Of PROHEMA In Inherited Metabolic Disorders 7/30/2014 7:58:29 AM
Lorus Therapeutics Inc. (LRP) Receives FDA Clearance Of IND To Initiate LOR-253 Clinical Program In Patients With AML, MDS And Other Blood Cancers 7/28/2014 7:33:53 AM
Stemline Therapeutics, Inc. (STML) Announces Opening Of SL-401 Corporate IND And Start Of Clinical Trials In BPDCN And AML 7/28/2014 7:46:22 AM
MacroGenics, Inc. (MGNX)'s DART Candidate IND For Colorectal Cancer, MGD007, Cleared To Start Enrolling Patients 7/25/2014 7:41:56 AM
Kinex Pharmaceuticals Announces Allowance Of The Investigational New Drug (IND) Application For KX2-391 Ointment By The United States FDA 7/24/2014 11:04:31 AM
1234567
//-->